The performance of screening tests for ovarian cancer: Results of a systematic review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 105, Issue 11, 1998, Pages 1136-1147

  Bell, Ruth ^a   Petticrew, Mark ^a   Sheldon, Trevor ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HUMAN; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; SCREENING TEST; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CA-125 ANTIGEN; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH;

EID: 0031728783     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1998.tb09966.x     Document Type: Article

References (50)

1. Black R, Macfarlane GJ, Maisonneuve P, Boyle P. Cancer incidence and mortality in Scotland1960–1989. Edinburgh Information and Statistics Division, NHS Scotland, 1995.
2. Kosary C. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynaecological system. Semin Surg Oncol 1994; 10 31–46.
3. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinu T, Esteve J. Survival of Cancer Patients in Europe. Lyon: IARC Scientific Publications, 1995.
4. Bourne T, Reynolds K, Campbell S. Ovarian cancer screening. Eur J Cancer 1991; 27: 655–659.
5. Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 1995; 75: 316–329.
6. Jacobs I, Bast RC. The CA125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1–12.
7. Randomised trial of screening for ovarian cancer (protocol): Ovarian Cancer Screening Unit, The Royal Hospitals Trust, 1995.
8. European Randomised Trial of Ovarian Cancer Screening (protocol): Wolfson Institute of Preventive Medicine, Department of Environmental and Preventive Medicine, 1995.
9. Kramer BS, Gohagan J, Prorok P, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal and ovarian carcinomas. Cancer 1993; 71 (Suppl): 589–593.
10. Bell R, Luengo S, Petticrew M, Sheldon T. Screening for ovarian cancer: a systematic review: Health Techno1 Assess 1998; 2 (2) i–iv: 1–84.
11. Cochrane Methods Working Group on Systematic Review of Screening and Diagnostic Tests. Recommended methods. Available at http://som.flinders.edu.au/FUSA/COCHRANE updated 6 June 1996.
12. Gardner S, Winter P, Gardner M. Confidence interval analysis software. Version 1.1, 1991.
13. Goswamy RK, Campbell S, Whitehead MI. Screening for ovarian cancer. Clin Obstet Gynaecol 1983; 10 621–643.
14. Andolf E, Svalenius E, Astedt B. Ultrasonography for early detection of ovarian carcinoma. Br J Obstet Gynaecol 1986; 93: 1286–1289.
15. Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J et al. Multimodal approach to screening for ovarian cancer. Lancet 1988; 1:268–271.
16. Campbell S, Bhan V, Royston P, Whitehead MI, Collins W. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989; 299: 1363–1367.
17. Millo R, Facca MC, Alberico S. Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer Clin Exp Obstet Gynecol 1989; 16: 72–78.
18. Demidov VN, Krasnikova SP, Terskaia LV. Role of echography in early detection of ovarian tumors. Voprosy Onkologii 1990; 36: 1365–1368.
19. Tabor A, Jensen FR, Bock JE, Hogdall CK. Feasibility study of a randomised trial of ovarian cancer screening. J Med Screen 1994; 1:215–219.
20. van Nagell JRJ, Gallion HH, Pavlik EJ, DePriest PD. Ovarian cancer screening. Cancer 1995; 76 (Suppl 10): 2086–2091.
21. Kurjak A, Shalan H, Kupesic S, Kosuta D, Sosic A, Benic S et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994; 13: 295–301.
22. Weiner Z, Beck D, Shteiner M, Borovik R, Ben-Shachar M, Robinzon E et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 1993; 12 387–393.
23. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic post menopausal women with color Doppler ultrasound. Cancer 1995; 76 1214–1218.
24. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993; 306: 1025–1029.
25. Parkes CA, Smith D, Wald NJ, Bourne TH. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen 1994; 1: 209–214.
26. Sato S, Hasuo Y, Ohta S, Maruyama H, Kagiya A. Mass-screen ing for ovarian cancer by means of transvaginal ultrasonography. Acta Obstet Gynaecol Jpn 1992; 44:683–688.
27. Schincaglia P, Brondelli L, Cicognani A, Buzzi G, Orsini LF, Bovicelli L et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity Tumori 1994; 80: 181–187.
28. Holbert TR. Screening transvaginal ultrasonography of postmen opausal women in a private office setting. Am J Obstet Gynecol 1994; 170: 1699–1703.
29. Akulenko LV, Garkavtseva RF, Zhordania KI, Samgina AA. Current status and perspectives for genetic consultation and prophylactic medical examination of risk groups with malignant neoplasms of the female reproductive system and breast. Tsitologiia i Genetika 1992; 26. 38–42.
30. Karlan BY, Raffel LJ, Crvenkovic G, Smrt C, Chen MD, Lopez E et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 1993; 169: 494–501.
31. Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993; 51: 12–20.
32. Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem 1995; 23 233–237.
33. Belinson JL, Okin C, Casey G, Ayoub A, Klein R, Hart WR et al. The familial ovarian cancer registry: progress report. Cleve Clin J Med 1995; 62: 129–134.
34. Dorum A, Kristensen GB, Abeler VM, Trope CG, Moller P. Early detection of familial ovarian cancer. Eur J Cancer 1996; 32 A: 1645–1651.
35. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996; 65: 221–225.
36. Grover S, Quinn MA, Weideman P, Koh H, Robinson HP, Rome R et al. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995; 5:291–295.
37. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 1993; 306: 1030–1034.
38. Bourne TH, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford TJ et al. The potential role of serum CA125 in an ultra sound-based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52: 379–385.
39. Vuento MH, Stenman UH, Pirhonen JP, Makinen JI, Laippala PJ, Salmi TA. Significance of a single CA125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol 1997; 64: 141–146.
40. Cuckle HS, Wald NJ. The evaluation of screening tests for ovarian cancer. In: Sharp F, Mason W, Leake R, editors. Ovarian Cancer. London: Chapman and Hall, 1990: 229–241.
41. Registrations of cancer diagnosed in 1991, England and Wales. Population and Health Monitor MBl 96/1. London: ONS, 1996.
42. Hennekens C, Buring J. Epidemiology in Medicine. Boston: Little Brown Medical, 1987.
43. Wardle JF, Collins W, Pernet AL, Whitehead MI, Bourne TH, Campbell LS. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993; 85: 653–657.
44. Skates SJ, Jacobs IJ, Sjovall K, Einhorn N, Xu F-J, Yu Y-H et al. High sensitivity and specificity of screening for ovarian cancer with the risk of ovarian cancer (ROC) algorithm based on rising CA125 levels. J Clin Oncol; 1996: 2007.
45. Jacobs IJ, Oram DH, Bast RCJ. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated anti gens CA125, CA15–13, and TAG 72.3. Obstet Gynecol 1992; 80: 396–399.
46. Office of Population and Census Survey. Mortality data, 1994.
47. Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic model to identify an efficient protocol for ovarian cancer screening. Controlled Clinical Trials 1997; 18: 251–270.
48. Calman K. Developing screening in the NHS. J Med Screen 1994; 1:101–105.
49. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805–812.
50. Jacobs I, Mackay J, Skates S. UKCCCR National Familial Ovarian Cancer Screening Study (protocol): UKCCCR Gynaecological Subcommittee, 1997.